Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
作者： L. Zhang , Y. Feng , J. List , S. Kasichayanula , M. Pfister
DOI: 10.1111/J.1463-1326.2010.01216.X
关键词:
摘要: Aim: Dapagliflozin is a stable, competitive, reversible, and highly selective inhibitor of sodium‐glucose co‐transporter 2, the major transporter responsible for renal glucose reabsorption. …
cabdirect.org
sci-hub.se 参考文章(12)
A. S. Poobalan, L. S. Aucott, W. C. S. Smith, A. Avenell, R. Jung, J. Broom, Long-term weight loss effects on all cause mortality in overweight/obese populations. Obesity Reviews. ,vol. 8, pp. 503- 513 ,(2007) , 10.1111/J.1467-789X.2007.00393.X
B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister, Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clinical Pharmacology & Therapeutics. ,vol. 85, pp. 513- 519 ,(2009) , 10.1038/CLPT.2008.250
Stephan Matthaei, Michael Stumvoll, Monika Kellerer, Hans-Ulrich Häring, Pathophysiology and pharmacological treatment of insulin resistance. Endocrine Reviews. ,vol. 21, pp. 585- 618 ,(2000) , 10.1210/EDRV.21.6.0413
H. King, R. E. Aubert, W. H. Herman, Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections Diabetes Care. ,vol. 21, pp. 1414- 1431 ,(1998) , 10.2337/DIACARE.21.9.1414
Stewart B. Harris, Jean-Marie Ekoé, Yola Zdanowicz, Susan Webster-Bogaert, Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study) Diabetes Research and Clinical Practice. ,vol. 70, pp. 90- 97 ,(2005) , 10.1016/J.DIABRES.2005.03.024
J. P.H. Wilding, P. Norwood, C. T'joen, A. Bastien, J. F. List, F. T. Fiedorek, A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment Diabetes Care. ,vol. 32, pp. 1656- 1662 ,(2009) , 10.2337/DC09-0517
J. F. List, V. Woo, E. Morales, W. Tang, F. T. Fiedorek, Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes Diabetes Care. ,vol. 32, pp. 650- 657 ,(2009) , 10.2337/DC08-1863
C. E. Koro, S. J. Bowlin, N. Bourgeois, D. O. Fedder, Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes: A preliminary report Diabetes Care. ,vol. 27, pp. 17- 20 ,(2004) , 10.2337/DIACARE.27.1.17
Anuar Zaini, Where is Malaysia in the midst of the Asian epidemic of diabetes mellitus? Diabetes Research and Clinical Practice. ,vol. 50, pp. S23- S28 ,(2000) , 10.1016/S0168-8227(00)00175-3
C A Cull, A Neil, Matthews, S E Manley, R R Holman, I M Stratton, H McElroy, E Kohner, R C Turner, C Fox, D Hadden, D Wright, Grp Ukpds., V Frighi, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) The Lancet. ,vol. 352, pp. 854- 865 ,(1998)